Drug Profile
ANT 2681
Alternative Names: ANT 2681; MBLi - AntabioLatest Information Update: 30 Jan 2023
Price :
$50
*
At a glance
- Originator Antabio
- Class Antibacterials; Small molecules
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 30 Jan 2023 ANT 2681 is still in preclinical development in Gram-negative-infections in France (Antabio website, January 2023)
- 30 Jan 2023 Antabio plans phase I trial in Urinary tract infection (Antabio website, January 2023)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Gram-negative-infections in France